검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Irinotecan liposomes (Irinotecan liposomes) Shanghai Runshi Pharmaceutical Tec…·Localized Advanced or Metastatic G… ORR 32% |
|---|---|
Overview Program | Irinotecan liposomes |
Overview Company | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
Overview Modality | ADC |
Overview Target | Localized Advanced or Metastatic Gastric |
Overview Indication | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Toxicology Major finding | Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.. Chemoresistance remains the major barrier to cancer treatment. Metabolic and epigenetic reprogramming are involved in this process; however, the precise roles and mechanisms are largely unknown. Here, we report that lactate-induced lactylation promo… |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT02489903 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Irinotecan liposomes (Irinotecan liposomes) Shanghai Runshi Pharmaceutical Tec…·Localized Advanced or Metastatic G… ORR 32% |
|---|---|
Overview Program | Irinotecan liposomes |
Overview Company | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
Overview Modality | ADC |
Overview Target | Localized Advanced or Metastatic Gastric |
Overview Indication | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Toxicology Major finding | Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair.. Chemoresistance remains the major barrier to cancer treatment. Metabolic and epigenetic reprogramming are involved in this process; however, the precise roles and mechanisms are largely unknown. Here, we report that lactate-induced lactylation promo… |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT02489903 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교